BFNH · Bioforce Nanosciences Holdings, Inc. · Insider Trading

$7.20 -0.35 (-4.64%) At close · Oct 5

Market Cap

$286.17M

33.55M

Volume · Oct 5 5807 Avg daily vol (3M) 9541

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-08-31	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Award↑ Filing footnotes — Common Stock; Par Value $0.001 (Direct) Reporting person received restricted shares in lieu of cash on a portion of accrued wages owed by the Company through April 30, 2026.	Common Stock; Par Value $0.001	316,909	$0.55	$174,300	1,234,447
2026-08-20	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Other↓ Filing footnotes — Common Stock; Par Value $0.001 (Direct) Reporting person paid a residential landscape contractor in shares in lieu of cash on an outstanding promissory note that was entered into in 2020 for the amount of $25,000.	Common Stock; Par Value $0.001	38,462	$0.65	$25,000	917,538
2026-04-22	Ferguson Merle	Director, CEO, 10% Owner	Sell↓	Common Stock; Par Value $0.001	26,700,000	$0.02	$400,500	0
2026-04-20	Ferguson Merle	Director, CEO, 10% Owner	Gift↑	Common Stock; Par Value $0.001	20,580,000	$0.01	$144,060	22,568,000
2026-04-20	Ferguson Merle	Director, CEO, 10% Owner	Gift↑	Common Stock; Par Value $0.001	4,132,000	$0.00	$4,132	26,700,000
2026-04-20	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Gift↓ Filing footnotes — Common Stock; Par Value $0.001 (Direct) 38,000 shares of this amount are held in YES INTERNATIONAL's name, an LLC that is 100% controlled by the reporting individual	Common Stock; Par Value $0.001	4,132,000	$0.00	$4,132	956,000
2023-10-18	Ferguson Merle	Director, CEO, 10% Owner	Gift↑	Common Stock	1,400,000	—	—	17,870,000
2023-10-17	Ferguson Merle	Director, CEO, 10% Owner	Gift↓ Filing footnotes — Common Stock (Indirect) 15,000,000 share are held directly by the reporting individual, 1,470,000 shares held indirectly in a business entity that the reporting person is an executive officer was gifted to the reporting person. The private company controlled by the reporting individual has -0- shares, no longer has shares of the issuer.	Common Stock (I)	1,470,000	—	—	15,000,000
2023-10-17	Ferguson Merle	Director, CEO, 10% Owner	Gift↑	Common Stock	1,470,000	—	—	16,470,000
2023-05-12	Ferguson Merle	Director, CEO, 10% Owner	Gift↓ Filing footnotes — Common Stock (Indirect) 15,000,000 share are held directly by the reporting individual, 1,470,000 shares held indirectly in a business entity that the reporting person is an executive officer. Total direct and indirect beneficial ownership is 16,470,000.	Common Stock (I)	500,000	—	—	16,470,000
2022-12-13	Ferguson Merle	Director, CEO, 10% Owner	Gift↓ Filing footnotes — Common Stock (Indirect) Bona fide gift of securities given to a third-party which is not a relative or related business entity. Securities gifted from an indirect entity that the reporting person is an executive officer. Gift transaction, price not applicable. 15,000,000 share are held directly by the reporting individual, 1,970,000 shares held indirectly in a business entity that the reporting person is an executive officer. Total direct and indirect beneficial ownership is 16,970,000. The reporting person is an Executive Officer of a private company, Trade Exchange International, Inc. Prior to the 20,000 share gift, Trade Exchange International, Inc. owned 1,990,000 share of the issuer; the current indirect holdings is now 1,970,000.	Common Stock (I)	20,000	—	—	16,970,000
2022-09-30	Ferguson Merle	Director, CEO, 10% Owner	Gift↓ Filing footnotes — Common Stock (Indirect) Bona fide gift of securities given to a third-party which is not a relative or related business entity. Securities gifted from an indirect entity that the reporting person is an executive officer. Gift transaction, price not applicable. 15,000,000 share are held directly by the reporting individual, 1,990,000 shares held indirectly in a business entity that the reporting person is an executive officer. Total direct and indirect beneficial ownership is 16,990,000. The reporting person is an Executive Officer of a private company, Trade Exchange International, Inc. Prior to the 10,000 share gift, Trade Exchange International, Inc. owned 2,000,000 share of the issuer; the current indirect holdings is now 1,990,000.	Common Stock (I)	10,000	—	—	16,990,000
2020-12-04	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Award↑ Filing footnotes — Common Stock (Direct) On December 4, 2020, BioForce Nanosciences Holdings, Inc. (The "Company" or the "Registrant") issued 3,000,000 shares of its common stock to the reporting individual in exchange for 500,000 shares of its Preferred Series 'A' shares. These shares were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933. The issuance was not a public offering as defined in Section4(2)due to the limited number of persons that received the shares, and the matter of the issuances. In addition, the transferee of the common stock represented that they had the necessary investment intent as required by Section 4(2) and agreed to receive shares containing a legend that states the securities were restricted pursuant to Rule 144 of the Securities Act.	Common Stock	3,000,000	$0.00	$3,000	5,050,000
2020-12-04	Ferguson Merle	Director, CEO, 10% Owner	Award↑ Filing footnotes — Common Stock (Direct) On December 4, 2020, BioForce Nanosciences Holdings, Inc. (The "Company" or the "Registrant") issued 11,000,000 shares of its common stock to the reporting individual in exchange for 1,500,000 shares of its Preferred Series 'A' shares. These shares were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933. The issuance was not a public offering as defined in Section4(2)due to the limited number of persons that received the shares, and the matter of the issuances. In addition, the transferee of the common stock represented that they had the necessary investment intent as required by Section 4(2) and agreed to receive shares containing a legend that states the securities were restricted pursuant to Rule 144 of the Securities Act.	Common Stock	11,000,000	$0.00	$11,000	15,000,000
2020-12-04	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Convert↓ Filing footnotes — Convetible Preferred 'A' (Direct) On December 4, 2020, BioForce Nanosciences Holdings, Inc. (The "Company" or the "Registrant") issued 3,000,000 shares of its common stock to the reporting individual in exchange for 500,000 shares of its Preferred Series 'A' shares. These shares were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933. The issuance was not a public offering as defined in Section4(2)due to the limited number of persons that received the shares, and the matter of the issuances. In addition, the transferee of the common stock represented that they had the necessary investment intent as required by Section 4(2) and agreed to receive shares containing a legend that states the securities were restricted pursuant to Rule 144 of the Securities Act.	Convetible Preferred 'A'	500,000	$0.00	$500	0
2020-12-04	Ferguson Merle	Director, CEO, 10% Owner	Convert↓ Filing footnotes — Convertible Preferred 'A' (Direct) On December 4, 2020, BioForce Nanosciences Holdings, Inc. (The "Company" or the "Registrant") issued 11,000,000 shares of its common stock to the reporting individual in exchange for 1,500,000 shares of its Preferred Series 'A' shares. These shares were issued pursuant to an exemption from registration provided by Section 4(2) of the Securities Act of 1933. The issuance was not a public offering as defined in Section4(2)due to the limited number of persons that received the shares, and the matter of the issuances. In addition, the transferee of the common stock represented that they had the necessary investment intent as required by Section 4(2) and agreed to receive shares containing a legend that states the securities were restricted pursuant to Rule 144 of the Securities Act.	Convertible Preferred 'A'	1,500,000	$0.00	$1,500	0
2020-03-31	KAISER RICHARD KAISER	Director, CFO, 10% Owner	Award↑ Filing footnotes — Convertible Preferred Series 'A' (Direct) Preferred Series 'A' have voting and conversion rights into Common Stock on a 100 to 1 basis.	Convertible Preferred Series 'A'	500,000	—	—	500,000
2020-03-31	Ferguson Merle	Director, CEO, 10% Owner	Award↑ Filing footnotes — Convertible Preferred Series 'A' (Direct) Preferred Series 'A' have voting and conversion rights into Common Stock on a 100 to 1 basis.	Convertible Preferred Series 'A'	1,500,000	—	—	1,500,000

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–18 of 18 transactions

Key facts CIK 1310488 CUSIP 09064C206 Visit website Investor relations